🔥🐔 BizChicken 🐔🔥

Companies Similar to Regulus Therapeutics Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Gossamer Bio, Inc.

Gossamer Bio, Inc. logo
Market Cap: Low
Employees: Low

GB002, GB004, GB5121, GB7208

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.

Tags: biopharmaceutical, central nervous system lymphoma, immunology, inflammation, inflammatory bowel disease, multiple sclerosis, oncology, pulmonary arterial hypertension, therapeutics

Symbol: GOSS

Recent Price: $0.88

Industry: Biotechnology

CEO: Mr. Faheem Hasnain

Sector: Healthcare

Employees: 135

Address: 3013 Science Park Road, San Diego, CA 92121

Phone: 858 684 1300

Leadership

  • Faheem Hasnain, Chairman
  • Richard Aranda, M.D., Chief Medical Officer
  • Jeff Boerneke, General Counsel and Secretary
  • Matt Cravets, Senior Vice President, Biometrics
  • Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
  • Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
  • Caryn Peterson, Executive Vice President, Regulatory Affairs
  • Bob Smith, Chief Commercial Officer
  • Christian Waage, Executive Vice President, Technical Operations & Administration
  • Deanna Weber, Senior Vice President, Human Resources
  • Russell J. Cox, Director
  • Thomas Daniel, Director
  • Skye Drynan, Director
  • Sandra Milligan, Director
  • Steven D. Nathan, Director
  • John Quisel, Director

Last updated: 2024-12-31

Structure Therapeutics Inc.

Structure Therapeutics Inc. logo
Market Cap: High
Employees: Low

GSBR-1290

Structure Therapeutics Inc. develops novel oral therapeutics for chronic diseases with unmet medical needs, focusing on conditions like type-2 diabetes, obesity, pulmonary, and cardiovascular diseases.

Tags: GPCR, biopharmaceutical, cardiovascular diseases, chronic diseases, obesity, oral therapeutics, pulmonary diseases, type-2 diabetes

Symbol: GPCR

Recent Price: $26.63

Industry: Biotechnology

CEO: Dr. Raymond C. Stevens Ph.D.

Sector: Healthcare

Employees: 136

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 628-229-9277

Last updated: 2024-12-31

Lumos Pharma, Inc.

Lumos Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

LUM-201

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for rare diseases, with its lead candidate LUM-201 in a Phase 2 trial for pediatric growth hormone deficiency.

Tags: biopharmaceutical, clinical trial, growth hormone, rare diseases, therapeutics

Symbol: LUMO

Recent Price: $4.34

Industry: Biotechnology

CEO: Mr. Richard J. Hawkins

Sector: Healthcare

Employees: 33

Address: 4200 Marathon Boulevard, Austin, TX 78756

Phone: 512 215 2630

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

REGENXBIO Inc.

REGENXBIO Inc. logo
Market Cap: Medium
Employees: Medium

NAV Technology Platform

REGENXBIO Inc. is a biotechnology company focusing on gene therapy product candidates to treat genetic defects and enable therapeutic protein production, using its proprietary NAV Technology Platform. Its lead candidate, RGX-314, is in Phase III trials for wet age-related macular degeneration.

Tags: Biotechnology, Clinical Trials, Gene Therapy, NAV Technology Platform, Therapeutic Proteins

Symbol: RGNX

Recent Price: $7.23

Industry: Biotechnology

CEO: Mr. Curran M. Simpson M.S.

Sector: Healthcare

Employees: 344

Address: 9804 Medical Center Drive, Rockville, MD 20850

Phone: 240 552 8181

Last updated: 2024-12-31

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

Tavalisse

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

Tags: biotechnology, cancer, drug development, hematologic disorders, immune diseases

Symbol: RIGL

Recent Price: $16.47

Industry: Biotechnology

CEO: Mr. Raul R. Rodriguez

Sector: Healthcare

Employees: 147

Address: 1180 Veterans Boulevard, South San Francisco, CA 94080

Phone: 650 624 1100

Last updated: 2024-12-31

Rallybio Corporation

Rallybio Corporation logo
Market Cap: Lowest
Employees: Lowest

RLYB212

Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for severe and rare diseases, with a lead product candidate RLYB212 in clinical trials.

Tags: biotechnology, clinical trials, monoclonal antibodies, rare diseases, therapeutics

Symbol: RLYB

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Stephen Uden M.B, M.D.

Sector: Healthcare

Employees: 25

Address: 234 Church Street, New Haven, CT 06510

Phone: 203 859 3820

Last updated: 2024-12-31

Soligenix, Inc.

Soligenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

SGX301 (Hy Bryte), SGX942, SGX203, SGX302

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.

Tags: Crohn's disease, SGX301, SGX942, biopharmaceutical, oral mucositis, psoriasis, rare diseases

Symbol: SNGX

Recent Price: $2.91

Industry: Biotechnology

CEO: Dr. Christopher J. Schaber Ph.D.

Sector: Healthcare

Employees: 13

Address: 29 Emmons Drive, Princeton, NJ 08540

Phone: 609 538 8200

Leadership

  • Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
  • Gregg A. Lapointe, CPA, MBA, Board Director
  • Diane L. Parks, MBA, Board Director
  • Robert J. Rubin, MD, Board Director
  • Jerome Zeldis, MD, PhD, Board Director

Last updated: 2024-12-31

TG Therapeutics, Inc.

TG Therapeutics, Inc. logo
Market Cap: High
Employees: Low

Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801

TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.

Tags: B-cell malignancies, BTK inhibitor, Cosibelimab, Ublituximab, Umbralisib, autoimmune diseases, biopharmaceutical

Symbol: TGTX

Recent Price: $31.45

Industry: Biotechnology

CEO: Mr. Michael S. Weiss Esq.

Sector: Healthcare

Employees: 264

Address: 2 Gansevoort Street, New York, NY 10014

Phone: 212 554 4484

Leadership

  • Michael S. Weiss, Chairman, President, and Chief Executive Officer
  • Sean A. Power, CPA, Chief Financial Officer
  • Adam Waldman, Chief Commercialization Officer

Last updated: 2024-12-31

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

ALG-010133

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, with a focus on chronic hepatitis B and non-alcoholic steatohepatitis.

Tags: NASH, biopharmaceutical, chronic hepatitis B, liver diseases, therapeutics

Symbol: ALGS

Recent Price: $40.47

Industry: Biotechnology

CEO: Dr. Lawrence M. Blatt MBA, Ph.D.

Sector: Healthcare

Employees: 68

Address: One Corporate Drive, South San Francisco, CA 94080

Phone: 800 466 6059

Last updated: 2024-12-31

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. logo
Market Cap: Medium
Employees: Low

RNA medicines

Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious and rare diseases, including programs for cystic fibrosis and ornithine transcarbamylase deficiency. The company collaborates with various partners for vaccine and therapeutic development.

Tags: RNA medicines, collaborations, infectious diseases, rare diseases, vaccines

Symbol: ARCT

Recent Price: $16.58

Industry: Biotechnology

CEO: Mr. Joseph E. Payne M.Sc.

Sector: Healthcare

Employees: 180

Address: 10628 Science Center Drive, San Diego, CA 92121

Phone: 858 900 2660

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31